These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 27411803)

  • 1. Physiologically Based Absorption Modeling to Design Extended-Release Clinical Products for an Ester Prodrug.
    Ding X; Day JS; Sperry DC
    AAPS J; 2016 Nov; 18(6):1424-1438. PubMed ID: 27411803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approaches to Account for Colon Absorption in Physiologically Based Biopharmaceutics Modeling of Extended-Release Drug Products.
    Jadhav H; Augustijns P; Tannergren C
    Mol Pharm; 2023 Dec; 20(12):6272-6288. PubMed ID: 37902586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting feasibility and characterizing performance of extended-release formulations using physiologically based pharmacokinetic modeling.
    Brown J; Crison J; Timmins P
    Ther Deliv; 2012 Sep; 3(9):1047-59. PubMed ID: 23035591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of drug property and product design on in vitro-in vivo correlation of complex modified-release dosage forms.
    Qiu Y; Li X; Duan JZ
    J Pharm Sci; 2014 Feb; 103(2):507-16. PubMed ID: 24338862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of PBPK Absorption Modeling to Guide Modified Release Formulation Development of Gaboxadol, a Highly Soluble Compound With Region-Dependent Absorption.
    Kesisoglou F; Balakrishnan A; Manser K
    J Pharm Sci; 2016 Feb; 105(2):722-728. PubMed ID: 26457884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low colonic absorption drugs: risks and opportunities in the development of oral extended release products.
    Xu J; Lin Y; Boulas P; Peterson ML
    Expert Opin Drug Deliv; 2018 Feb; 15(2):197-211. PubMed ID: 28988504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Deconvolution-Based and Absorption Modeling IVIVC for Extended Release Formulations of a BCS III Drug Development Candidate.
    Kesisoglou F; Xia B; Agrawal NG
    AAPS J; 2015 Nov; 17(6):1492-500. PubMed ID: 26290380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug.
    Brown J; Chien C; Timmins P; Dennis A; Doll W; Sandefer E; Page R; Nettles RE; Zhu L; Grasela D
    J Pharm Sci; 2013 Jun; 102(6):1742-1751. PubMed ID: 23681563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of Absorption Modeling in Rational Design of Drug Product Under Quality-by-Design Paradigm.
    Kesisoglou F; Mitra A
    AAPS J; 2015 Sep; 17(5):1224-36. PubMed ID: 26002509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of Physiologically Based Absorption Modeling for Amphetamine Salts Drug Products in Generic Drug Evaluation.
    Babiskin AH; Zhang X
    J Pharm Sci; 2015 Sep; 104(9):3170-82. PubMed ID: 25973928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of In Vivo Clinical Product Performance of a Weak Basic Drug by Integration of In Vitro Dissolution Tests and Physiologically Based Absorption Modeling.
    Ding X; Gueorguieva I; Wesley JA; Burns LJ; Coutant CA
    AAPS J; 2015 Nov; 17(6):1395-406. PubMed ID: 26126932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Drug Properties and Formulation on In Vitro Drug Release and Biowaiver Regulation of Oral Extended Release Dosage Forms.
    Lin Z; Zhou D; Hoag S; Qiu Y
    AAPS J; 2016 Mar; 18(2):333-45. PubMed ID: 26769249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive- extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects.
    Gordi T; Hou E; Kasichayanula S; Berner B
    Clin Ther; 2008 May; 30(5):909-16. PubMed ID: 18555937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
    Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suitability of a minipig model in assessing clinical bioperformance of matrix and multiparticulate extended-release formulations for a BCS class III Drug development candidate.
    Kesisoglou F; Xie IH; Manser K; Wu Y; Hardy I; Fitzpatrick S
    J Pharm Sci; 2014 Feb; 103(2):636-42. PubMed ID: 24382706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
    Jenner P; Könen-Bergmann M; Schepers C; Haertter S
    Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of LY545694 tosylate controlled release tablets through pharmacoscintigraphy.
    Lobo ED; Argentine MD; Sperry DC; Connor A; McDermott J; Stevens L; Almaya A
    Pharm Res; 2012 Oct; 29(10):2912-25. PubMed ID: 22695731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro-in vivo-in silico approach in biopharmaceutical characterization of ibuprofen IR and SR tablets.
    Beloica S; Cvijić S; Bogataj M; Parojčić J
    Eur J Pharm Sci; 2015 Jul; 75():151-9. PubMed ID: 25861718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.